Bristol Myers Squibb

News

Cytokinetics' president and chief executive Robert Blum

FDA kicks off review of Cytokinetics' aficamten for HCM

Cytokinetics should hear back from the FDA next September about its application for Camzyos rival aficamten in obstructive hypertrophic cardiomyopathy

News

BMS files legal challenge to HHS' 340B rebate decision

Bristol-Myers Squibb has become the latest pharma in the US to file a legal challenge to a block on a 340B drug rebate model opposed by HRSA.

News

Schizophrenia highlighted in a list of definitions of disorders

Advantage BMS as AbbVie drug fails schizophrenia trials

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

News

Pharmas ask appeals court to reconsider IRA lawsuits

The pharma industry's challenge to Medicare drug price negotiation powers continues to rumble on, with three drugmakers asking a US appeals court to revive their lawsuits.

News

FDA approval gives BMS an edge in NSCLC treatment

Bristol Myers Squibb (BMS) has secured

News

BMS ends decades-long drought in novel schizophrenia drugs

Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal.

FDA kicks off review of Cytokinetics' aficamten for HCM

BMS files legal challenge to HHS' 340B rebate decision

Advantage BMS as AbbVie drug fails schizophrenia trials

Pharmas ask appeals court to reconsider IRA lawsuits

FDA approval gives BMS an edge in NSCLC treatment

BMS ends decades-long drought in novel schizophrenia drugs

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks